Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States

被引：78

作者：

Apperley, Jane ^{[1
]}

Niederwieser, Dietger ^{[2
]}

Huang, Xiao-jun ^{[3
]}

Nagler, Arnon ^{[4
,5
]}

Fuchs, Ephraim ^{[6
]}

Szer, Jeff ^{[7
,8
]}

Kodera, Yoshihisa ^{[9
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England

[2] Univ Leipzig, Div Hematol & Med Oncol, D-04109 Leipzig, Germany

[3] Peking Univ, Peoples Hosp, Beijing Key Lab HSCT, Inst Hematol, Beijing 100871, Peoples R China

[4] Chaim Sheba Med Ctr, Div Hematol, BMT, IL-52621 Tel Hashomer, Israel

[5] Chaim Sheba Med Ctr, Cord Blood Bank, IL-52621 Tel Hashomer, Israel

[6] Johns Hopkins Univ, Blood & Bone Marrow Canc Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[7] Royal Melbourne Hosp, Dept Clin Haematol, Melbourne, Vic, Australia

[8] Royal Melbourne Hosp, BMT Serv, Melbourne, Vic, Australia

[9] Aichi Med Univ, Sch Med, Dept Promot Blood & Marrow Transplantat, Nagakute, Aichi 4801195, Japan

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2016年 / 22卷 / 01期

关键词：

Global Activity Survey; Haplo-transplantation; Haplo-HSCT; Beijing Protocol; Europe; United States; BONE-MARROW TRANSPLANTS; HLA-IDENTICAL SIBLINGS; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; ACUTE-LEUKEMIA; CORD BLOOD; DONORS; SURVIVAL; DISEASE; MALIGNANCIES; ENGRAFTMENT;

D O I：

10.1016/j.bbmt.2015.11.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

One of the major projects of the Worldwide Network for Blood and Marrow Transplantation (WBMT) is to promote hematopoietic stem cell transplantation (HSCT) in emerging countries in the world. For these countries, HLA haploidentical HSCT (haplo-HSCT) from family members is an attractive approach because of its cost effectiveness. To learn the current status, including recent trends, of haplo-HSCT, the WBMT invited speakers from major transplant centers in 3 regions (Asia, Europe, and North America) to present at its annual WBMT Joint Session. This article represents the direct reports from these 3 speakers in addition to introductions by 2 WBMT speakers who address data from the Global Transplant Activity survey. It must be emphasized, however, that certain promising results of haplo-HSCT presented in this article were obtained at well-experienced institutes. (C) 2016 American Society for Blood and Marrow Transplantation.

引用

页码：23 / 26

页数：4

共 26 条

[1] EFFECT OF HLA INCOMPATIBILITY ON GRAFT-VERSUS-HOST DISEASE, RELAPSE, AND SURVIVAL AFTER MARROW TRANSPLANTATION FOR PATIENTS WITH LEUKEMIA OR LYMPHOMA [J].

ANASETTI, C ;

BEATTY, PG ;

STORB, R ;

MARTIN, PJ ;

MORI, M ;

SANDERS, JE ;

THOMAS, ED ;

HANSEN, JA .

HUMAN IMMUNOLOGY, 1990, 29 (02) :79-91

[2] EFFECT OF HLA COMPATIBILITY ON ENGRAFTMENT OF BONE-MARROW TRANSPLANTS IN PATIENTS WITH LEUKEMIA OR LYMPHOMA [J].

ANASETTI, C ;

AMOS, D ;

BEATTY, PG ;

APPELBAUM, FR ;

BENSINGER, W ;

BUCKNER, CD ;

CLIFT, R ;

DONEY, K ;

MARTIN, PJ ;

MICKELSON, E ;

NISPEROS, B ;

OQUIGLEY, J ;

RAMBERG, R ;

SANDERS, JE ;

STEWART, P ;

STORB, R ;

SULLIVAN, KM ;

WITHERSPOON, RP ;

THOMAS, ED ;

HANSEN, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (04) :197-204

[3] A disease risk index for patients undergoing allogeneic stem cell transplantation [J].

Armand, Philippe ;

Gibson, Christopher J. ;

Cutler, Corey ;

Ho, Vincent T. ;

Koreth, John ;

Alyea, Edwin P. ;

Ritz, Jerome ;

Sorror, Mohamed L. ;

Lee, Stephanie J. ;

Deeg, H. Joachim ;

Storer, Barry E. ;

Appelbaum, Frederick R. ;

Antin, Joseph H. ;

Soiffer, Robert J. ;

Kim, Haesook T. .

BLOOD, 2012, 120 (04) :905-913

[4]

ASH RC, 1991, BONE MARROW TRANSPL, V7, P443

[5] Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].

Aversa, F ;

Tabilio, A ;

Velardi, A ;

Cunningham, I ;

Terenzi, A ;

Falzetti, F ;

Ruggeri, L ;

Barbabietola, G ;

Aristei, C ;

Latini, P ;

Reisner, Y ;

Martelli, MF .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193

[6]

Bashey A, 2011, BLOOD, V118, P833

[7] PROLONGATION OF HOMOGRAFT SURVIVAL IN MICE WITH SINGLE DOSES OF CYCLOPHOSPHAMIDE [J].

BERENBAUM, MC ;

BROWN, IN .

NATURE, 1963, 200 (490) :84-&

[8] Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre [J].

Bilmon, I. A. ;

Kwan, J. ;

Gottlieb, D. ;

Kerridge, I. ;

McGurgan, M. ;

Huang, G. ;

George, B. ;

Hertzberg, M. ;

Bradstock, K. F. .

INTERNAL MEDICINE JOURNAL, 2013, 43 (02) :191-196

[9] HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease [J].

Bolanos-Meade, Javier ;

Fuchs, Ephraim J. ;

Luznik, Leo ;

Lanzkron, Sophie M. ;

Gamper, Christopher J. ;

Jones, Richard J. ;

Brodsky, Robert A. .

BLOOD, 2012, 120 (22) :4285-4291

[10] Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas [J].

Castagna, L. ;

Bramanti, S. ;

Furst, S. ;

Giordano, L. ;

Crocchiolo, R. ;

Sarina, B. ;

Mauro, E. ;

Morabito, L. ;

Bouabdallah, R. ;

Coso, D. ;

Balzarotti, M. ;

Broussais, F. ;

El-Cheikh, J. ;

Stella, C. C. ;

Brusamolino, E. ;

Blaise, D. ;

Santoro, A. .

BONE MARROW TRANSPLANTATION, 2014, 49 (12) :1475-1480

← 1 2 3 →